Shots:

• Novartis to get minority equity in Anthos and will grant rights to Anthos for MAA868 to develop in CVD. Blackstone Life Sciences to fund the joint venture with $250M and will take care of development of all products
• The focus of the agreement is to build a joint venture i.e  Anthos Therapeutics developing anti-thrombotic therapies for patients with high-risk cardiovascular disorders
• Novartis’ MAA868 is a mAb with anti- Factor XI / XIa involved in prevention of thrombotic disorders with minimal or no bleeding risk

Ref: Anthos Therapeutics | Image: Anthos Therapeutics